NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

NexImmune, Inc. announces the extension of the research partnership between NexImmune, Yale, and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete, or modulate diabetes antigen-specific T cells.